Climb Historical Income Statement
| CLYM Stock | 1.95 0.08 3.94% |
Historical analysis of Climb Bio income statement accounts such as Total Revenue of 0.0, Research Development of 20.4 M or Total Operating Expenses of 36.5 M can show how well Climb Bio performed in making a profits. Evaluating Climb Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Climb Bio's future profits or losses.
Climb Bio Net Income |
|
Climb |
About Climb Income Statement Analysis
Climb Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Climb Bio shareholders. The income statement also shows Climb investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Climb Bio Income Statement Chart
Total Revenue
Total revenue comprises all receipts Climb Bio generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Climb Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Climb Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.At this time, Climb Bio's Research Development is very stable compared to the past year. As of the 20th of December 2024, Total Other Income Expense Net is likely to grow to about 562.8 K, while Selling General Administrative is likely to drop about 16.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 35.7M | 45.1M | 40.3M | 36.5M | Research Development | 23.3M | 26.2M | 15.4M | 20.4M |
Climb Bio income statement Correlations
Click cells to compare fundamentals
Climb Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.